文献速递睡眠呼吸障碍

设计受体技术经舌内给药激活颏舌肌治疗睡眠呼吸障碍

Designer Receptors Exclusively Activated by Designer Drugs Approach to Treatment of Sleep-disordered Breathing.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

研究在饮食诱导肥胖小鼠中经舌内注射AAV9-DREADD,评估新型配体J60对颏舌肌活性、咽部通畅性及睡眠呼吸的影响。结果显示J60使颏舌肌紧张性活动增加超过6倍、舌组织摄取示踪剂增加1.5倍,并改善非快速眼动睡眠期咽部通畅性、解除上气道阻塞。提示该策略可能成为睡眠呼吸暂停的新治疗方向。

要点

  • 舌内注射AAV9-DREADD后,J60可激活颏舌肌并改善咽部通畅性。
  • J60使颏舌肌紧张性活动增加超过6倍,舌组织示踪剂摄取增加1.5倍。
  • J60在非快速眼动睡眠期解除上气道阻塞。

核心结论

  • 经舌内给予AAV9-DREADD后,J60可激活颏舌肌、改善咽部通畅性及睡眠期呼吸。

研究设计与样本

  • 在饮食诱导肥胖小鼠睡眠呼吸障碍模型中,经舌内注射AAV9-hSyn-hM3(Gq)-mCherry或对照AAV9,观察J60对颏舌肌活性、咽部通畅性及睡眠呼吸的影响。

主要发现

  • 与对照相比,J60使颏舌肌紧张性活动增加超过6倍。
  • J60使舌组织摄取2-脱氧-2-[18F]氟-D-葡萄糖增加1.5倍。
  • J60增加咽部通畅性并解除非快速眼动睡眠期上气道阻塞。

局限性

  • 研究为饮食诱导肥胖小鼠模型,尚需进一步验证临床转化潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Obstructive sleep apnea is recurrent upper airway obstruction caused by a loss of upper airway muscle tone during sleep. The main goal of our study was to determine if designer receptors exclusively activated by designer drugs (DREADD) could be used to activate the genioglossus muscle as a potential novel treatment strategy for sleep apnea. We have previously shown that the prototypical DREADD ligand clozapine-N-oxide increased pharyngeal diameter in mice expressing DREADD in the hypoglossal nucleus. However, the need for direct brainstem viral injections and clozapine-N-oxide toxicity diminished translational potential of this approach, and breathing during sleep was not examined.Objectives: Here, we took advantage of our model of sleep-disordered breathing in diet-induced obese mice, retrograde properties of the adeno-associated virus serotype 9 (AAV9) viral vector, and the novel DREADD ligand J60.Methods: We administered AAV9-hSyn-hM3(Gq)-mCherry or control AAV9 into the genioglossus muscle of diet-induced obese mice and examined the effect of J60 on genioglossus activity, pharyngeal patency, and breathing during sleep.Measurements and Main Results: Compared with control, J60 increased genioglossus tonic activity by greater than sixfold and tongue uptake of 2-deoxy-2-[18F]fluoro-d-glucose by 1.5-fold. J60 increased pharyngeal patency and relieved upper airway obstruction during non-REM sleep.Conclusions: We conclude that following intralingual administration of AAV9-DREADD, J60 can activate the genioglossus muscle and improve pharyngeal patency and breathing during sleep.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Fleury Curado T, Pho H, Freire C, et al. Designer Receptors Exclusively Activated by Designer Drugs Approach to Treatment of Sleep-disordered Breathing. Am J Respir Crit Care Med. 2021. PMID: 32673075. doi:10.1164/rccm.202002-0321OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。